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The Journal of Immunology
IRAK1 Limits TLR3/4- and IFNAR-Driven IL-27 Production
through a STAT1-Dependent Mechanism
Daniela Bruni,*,1 Adam Dignam,*,1 Susan Dunne,*,1 Devlin Wall-Coughlan,*
Aisling McCrudden,* Karen O’Connell,†,‡ Caitriona Lyons,* Christopher McGuigan,†,‡
Niall Tubridy,†,‡ and Marion P. Butler*
IL-27 is a cytokine exerting pleiotropic immunomodulatory effects on a broad spectrum of immune cells. Optimal IL-27 pro-
duction downstream of TLR3/4 ligand stimulation relies on autocrine type I IFN signaling, defining a first and second phase in
IL-27 production. This work shows that IL-1 receptor-associated kinase 1 (IRAK1) limits TLR3/4- and IFNAR-induced IL-27
production. At the mechanistic level, we identified IRAK1 as a novel regulator of STAT1, IRF1, and IRF9. We found hyper-
activation of STAT1 together with increased nuclear levels of IRF1 and IRF9 in IRAK1-deficient murine macrophages compared
with control cells following stimulation with LPS and poly(I:C). IRAK1-deficient human microglial cells showed higher basal
levels of STAT1 and STAT2 compared with control cells. Blocking the kinase activity of TBK1/IKK« in IRAK1 knockdown human
microglial cells reduced the high basal levels of STAT1/2, uncovering a TBK1/IKK« kinase–dependent mechanism controlling
basal levels of STAT1/2. Stimulating IRAK1 knockdown human microglial cells with IFN-b led to increased IL-27p28 expression
compared with control cells. In IRAK1-deficient murine macrophages, increased IL-27 levels were detected by ELISA following
IFN-b stimulation compared with control macrophages together with increased nuclear levels of p-STAT1, IRF1, and IRF9.
Treatment of wild-type and IRAK1-deficient murine macrophages with fludarabine similarly reduced TLR3/4-induced IL-27
cytokine levels. To our knowledge, this work represents the first report placing IRAK1 in the IFNAR pathway and identifies
IRAK1 as an important regulator of STAT1, controlling IL-27 production downstream of TLR3/4 and IFNAR signaling
pathways. The Journal of Immunology, 2018, 201: 2070–2081.
I
nterleukin 27 is a heterodimeric cytokine composed of the
subunits EBV-induced gene 3 (EBI3) and IL-27p28 (1) and
is a member of a family of cytokines that includes IL-12,
IL-23, and IL-35. IL-27 is mainly produced by monocytes, mac-
rophages, dendritic cells, and microglial cells in response to
TLR3, -4, and -9 ligand stimulation (2, 3). Optimal IL-27p28
expression relies on autocrine type I IFN signaling following
TLR ligand stimulation (4). IL-27 binds to a heterodimeric cell
surface receptor that consists of two subunits: gp130, which be-
longs to the IL-6 family and is shared by many other cytokine
receptors, and IL-27Ra (WSX1/TCCR). IL-27Ra specifically
recognizes IL-27, and consequently, IL-27Ra distribution deter-
mines the cellular targets of IL-27. IL-27Ra is expressed on
T cells, B cells, NK cells, neutrophils, monocytes, mast cells, and
at lower levels on macrophages and endothelial cells (5). Upon
IL-27 binding, IL-27R becomes activated, initiating a signaling
cascade that involves several members of the JAK/STAT pathway,
notably STAT1 and STAT3. IL-27 prevents the differentiation of
Th2, Th17, and regulatory T cells by suppressing the corre-
sponding master transcription factors GATA-3, ROR-gt, and
FOXP3, respectively (6–8). In contrast, IL-27 promotes Th1 po-
larization and synergizes with IL-12 in the production of the Th1
signature cytokine IFN-g (9, 10). IL-27 also supports the differ-
entiation of naive CD4+ T cells into the IL-10–producing T reg-
ulatory 1 cells, which are often deregulated in autoimmune
diseases (11–13).
IL-27 reduces disease severity in several animal models of
autoimmune diseases, including those representing multiple scle-
rosis (MS) and rheumatoid arthritis, through suppressing the de-
velopment of pathogenic Th17 cells (14–18). Studies in
rheumatoid arthritis have shown that CD14+ mononuclear cells are
the key cellular sources of IL-27 that infiltrate into the synovium
of arthritic joints, reducing inflammation (19). Studies involving
newly diagnosed and progressive MS patients showed reduced
plasma/serum levels of IL-27 when compared with healthy control
subjects (20–22). In progressive MS, plasma levels of IL-27
negatively correlated with both the percentages of circulating
Th17 cells and plasma levels of IL-17 (20).
IL-27 also exerts antitumor activities through the upregulation of
Th1, CD8+ CTL, and NK cell responses, key immune cell players
in mediating the antitumor immune response (23–28).
TLR-induced expression of EBI3 in dendritic cells is dependent
on NF-kB and PU.1 (29). The IL-27p28 promoter has a distal
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NF-kB site as well as an IFN-stimulated regulatory element
(ISRE) site. Following TLR3/4 engagement, the transcription
factors IRF3 and NF-kB become activated, and both drive
IL-27p28 and IFN-b gene expression (2, 30). The TLR4–MyD88-
dependent pathway also leads to the activation of IRF1 (31, 32)
and IRF8 (33), which bind to an ISRE in the IL-27p28 promoter,
driving p28 subunit expression. Autocrine type I IFN signaling
leads to a STAT1-dependent increase in IRF1 expression and
sustained activation of IRF1 follows. IRF1 binds to an ISRE site in
the p28 promoter. Importantly, type I IFN results in the activation
of the IFN-stimulated gene factor 3 (ISGF3) (STAT1/STAT2/
IRF9) complex, which is also recruited to the ISRE site in the
p28 promoter, amplifying IL-27p28 gene expression (4, 34).
ISGF3 also leads to IRF7 gene induction, thereby amplifying
IFN-b production, which acts to positively influence IL-27p28
gene expression. TLR3 and -4 pathway-specific differences
exist, including the dynamics and intensity of IL-27p28 gene
activation as well as their differential dependency on IRF tran-
scription factors mediating IL-27p28 expression (4).
This study identified IRAK1 as a pivotal signaling molecule
controlling IL-27 production induced by TLR3 and -4 ligands.
Optimal IL-27 production following TLR ligand stimulation relies
on autocrine type I IFN signaling. Based on our mechanistic
findings, we explored whether IRAK1 acts downstream of IFN-a
receptor (IFNAR). Our findings place IRAK1 downstream of
IFNAR, regulating the STAT1/ISGF3 signaling axis controlling
IL-27 cytokine production.
Materials and Methods
Cell lines
Wild-type (WT) and IRAK12/2 bone marrow–derived macrophages (BMDM),
TBK12/2TNFR12/2 BMDM, and the control cell line TBK1+/+ TNFR12/2
BMDM were gifts from Dr. K. Fitzgerald (University of Massachusetts
Medical School, Worcester, MA). The human microglial cell line CHME3
was provided by Dr. M. Naghavi (Columbia University, New York, NY).
Abs and reagents
Anti–phospho-STAT1, both Ser727 and Tyr701, anti-IRAK1, and anti-IRF1
were purchased from Santa Cruz Biotechnology. Anti–phospho-IRF3
(Ser396) and anti-IRF1 (human) were from Cell Signaling Technology.
b-Actin was from Sigma-Aldrich and anti-IRF9 from R&D Systems and
Cell Signaling Technology. Poly(I:C) (high molecular weight) (InvivoGen)
was used at a final concentration of 25 mg/ml. LPS (Enzo Life Sciences)
was used at a final concentration of 1 mg/ml. Human IFN-b (hIFN-b)
(ImmunoTools) and murine IFN-b (mIFN-b) (R&D Systems) were used at
a final concentration of 10 ng/ml. The dual IKKε/TBK1 kinase inhibitor
MRT67307 was purchased from the Medical Research Council Protein
Phosphorylation and Ubiquitylation Unit, University of Dundee and was
used at a final concentration of 2 mM. Fludarabine (Sigma-Aldrich) was
used at a 50-mM final concentration.
Western blot analysis
Following a time course of stimulation using poly(I:C) (25 mg/ml), LPS
(1 mg/ml), or IFN-b (10 ng/ml), cells were lysed in lysis buffer containing
50 mM Tris HCl (pH 7.5), 150 mM sodium chloride, 0.5% (v/v) IGEPAL,
50 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM DTT, 1 mM
PMSF, and protease inhibitor mixture (Roche). The lysates were resolved
by SDS-PAGE, transferred to PVDF (GE Healthcare), and probed with the
indicated Abs. Where relevant, nuclear and cytosolic fractionation was
performed using the Nuclear Extract Kit (Active Motif) as per manufac-
turer’s instructions.
Real-time PCR
Total RNA was extracted from cell cultures using TRI Reagent (Sigma-
Aldrich). Total RNA was reverse transcribed to cDNA using All-In-One
RT MasterMix (ABMgood) according to the manufacturer’s instructions.
Quantitative real-time PCR was performed on a StepOnePlus Real-Time
PCR System (Applied Biosystems) using the FastStart Universal SYBR
Green Master Mix (Rox) (Roche). The data were analyzed using
the 22DDCt relative method, with all samples normalized to GAPDH.
All experiments were conducted in triplicate. Primer sequences used in
this study for amplification of murine and human target genes are
provided in Table I.
ELISA
ELISAs were used to measure the levels of murine IL-27 in the supernatant
of WTand IRAK2/2 BMDM using the Mouse IL-27 ELISA Ready-SET-Go!
from eBioscience. BMDM were seeded at 1 3 106/ml and stimulated with
poly(I:C) (25 mg/ml) for 9 h, LPS (1 mg/ml) for 6 h, or IFN-b for 8 h.
Where specified, cells were pretreated with inhibitors, as detailed in the
figure legends. CHME3 cells were seeded at 5 3 106 cells/ml and stim-
ulated for 12 h with poly(I:C) or LPS, supernatants were collected, and
the levels of IL-27 were measured by ELISA (eBioscience). All ELISAs
were conducted at least in triplicate and according to the manufacturer’s
instructions. The average (6SEM) was calculated for at least three ex-
periments except in the case of patients’ samples.
Lentiviral knockdown
HEK293T cells were transfected using GeneJuice (Novagen) according to
the manufacturer’s instructions with the packaging plasmid pCMV-dR 8.91
(1 mg), envelope plasmid VSV-G (1 mg) and IRAK1 sh-pLKO.1 vector
(2 mg; Sigma-Aldrich), or control short hairpin RNA (shRNA) (Sigma-
Aldrich). The control shRNA was a nontargeting shRNA vector. Medium
was replaced 24 h posttransfection with a 30% (v/v) FBS-containing
medium for a further 24 h. The lentivirus-containing medium was har-
vested 24 h later, fresh medium was added, and lentiviral particles were
collected again 24 h later. CHME3 cells seeded into T75 flasks were
transduced with 2 ml lentivirus-containing medium with hexadimethrine
bromide (8 mg/ml) and incubated for 24 h prior to adding puromycin
(2 mg/ml), which positively selected cells with integrated shRNA con-
structs.
Statistical analysis
Data analysis was carried out using the unpaired Student t test: *p , 0.05,
**p , 0.01, ***p , 0.001. When data, tested using the D’Agostino–
Pearson omnibus normality test, were not normally distributed, the p value
was calculated using the Mann–Whitney U test. One-way ANOVA with a
post hoc Tukey test was conducted for multiple experimental group
comparison.
Results
Probing TLR-regulated IL-27 production reveals a novel role
for IRAK1 in limiting IL-27 production downstream of TLR3
and TLR4
Measuring IL-27 levels by ELISA in poly(I:C)-treated WT and
IRAK1-deficient BMDM revealed a significant increase in IL-27
production in IRAK12/2 macrophages [p , 0.01 and p , 0.05,
6 and 9 h of poly(I:C), respectively; Fig. 1A]. Similarly, height-
ened IL-27 production was observed in TLR4 ligand–stimulated,
IRAK1-deficient macrophages compared with WT macrophages
(p , 0.05, following 6 h of LPS; Fig. 1A). IRF3 has been shown
to be critically involved in TLR4-induced and, to a lesser extent,
TLR3-induced IL-27p28 expression (4). Given the importance
of TBK1 in IRF3 activation and IFN-b production downstream
of these TLRs, we next assessed whether inhibiting the kinase
activity of TBK1 reduced both TLR3- and 4-induced IL-27 cy-
tokine responses. Pretreating WT BMDM with MRT67307, a dual
TBK1/IKKε kinase inhibitor, led to a significant reduction in both
TLR4- and TLR3-induced IL-27 production (p , 0.05; Fig. 1B).
We next tested whether the dual TBK1/IKKε kinase inhibitor,
MRT67307, could reduce the TLR-induced hyper–IL-27 cytokine
response observed in IRAK1-deficient macrophages similarly to
that seen in inhibitor-treated WT macrophages. Using MRT67307,
we observed significantly reduced IL-27 production in IRAK12/2
BMDM following LPS stimulation (p , 0.05), with a less pro-
nounced reduction seen in poly(I:C) ligand–stimulated IRAK12/2
BMDM (Fig. 1C). This finding suggested a functional difference
between the TLR3 versus TLR4 signaling pathways involving the
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FIGURE 1. IRAK1 limits TLR3- and TLR4-driven IL-27 production, in part through TBK1-dependent mechanisms. (A) WT or IRAK12/2 BMDM were
seeded and stimulated with 25 mg/ml poly(I:C) or 1 mg/ml LPS. Supernatants were collected after 6 and 9 h, and IL-27 levels were measured through
ELISA. Data are the mean (6SEM) of three independent experiments performed in triplicate. The p values were calculated using the unpaired Student
t test. (B) Kinase-active TBK1/IKKε has a major role in the regulation of IL-27 production downstream of TLR3 or TLR4. WT BMDM were seeded and
stimulated for 9 h with 25 mg/ml poly(I:C) or for 6 h with 1 mg/ml LPS. Cells had been pretreated with 2 mM MRT67307 (dual TBK1/IKKε kinase
inhibitor) or the same volume of DMSO as a vehicle control. Supernatants were collected, and IL-27 levels were measured by ELISA. Data shown are the
mean (6SEM) of four independent experiments performed in duplicate. The data, tested using the D’Agostino–Pearson omnibus normality test, were not
normally distributed, and thus the p value was calculated using the Mann–Whitney U test. (C) MRT67307 reduces the heightened IL-27 cytokine levels
observed in IRAK1-deficient macrophages following LPS and poly(I:C) stimulation. WT and IRAK1-deficient BMDM were seeded; the next day, cells
were treated with DMSO or the TBK1/IKKε kinase inhibitor MRT67307 (2 mM) for 1 h prior to poly(I:C) or LPS stimulation. After 6 h, the supernatant
was collected and analyzed for IL-27 by ELISA. Data are shown as mean (6SEM) of three independent experiments. The p value was calculated using the
unpaired Student t test. (D–F) IRAK1 regulates the transcription of IFN-b, IL-27p28, and EBI3. WT or IRAK12/2 BMDM were seeded and stimulated for
3 h with 25 mg/ml poly(I:C) or 1 mg/ml LPS. Cells had been pretreated with 2 mM MRT67307 or the same volume of DMSO as a vehicle control. Total
RNAwas isolated and subjected to reverse transcription. IFN-b, IL-27p28, and EBI3 mRNAwas measured by quantitative real-time RT-PCR, normalized
against GAPDH mRNA, and shown as the mean (6SEM) of three independent experiments performed in triplicate. One-way ANOVA with a post hoc
Tukey test was conducted for multiple experimental group comparison. *p , 0.05, **p , 0.01, ***p , 0.001. NL, no ligand.
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regulation of IL-27 production in IRAK1–deficient macrophages.
Because optimal IL-27 production relies on autocrine IFN-b
signaling, we tested the impact of MRT67307 on type I IFN ex-
pression, analyzing IFN-b mRNA expression in MRT67307-
treated WT and IRAK12/2 BMDM stimulated with LPS and
poly(I:C) (Fig. 1D). MRT67307 inhibited TLR3/4-induced IFN-b
expression in WT BMDM and in LPS-stimulated IRAK12/2
macrophages. In contrast, we detected high levels of IFN-b in
poly(I:C)-stimulated IRAK12/2 compared with WT macrophages
(35), which we found to remain high following MRT67307
treatment (Fig. 1D). This means that for TLR3 responses, the
second phase in IL27p28 expression involving the IFNAR sig-
naling pathway remains active in MRT67307-treated IRAK12/2
cells, giving understanding to the differences observed between
TLR3 and TLR4 responses (Fig. 1C).
We next examined IL-27 at the transcriptional level, measuring
p28 and EBI3 subunit expression by quantitative RT-PCR (qRT-
PCR) (Table I) in LPS- and poly(I:C)-stimulated WT and IRAK1-
deficient macrophages. Supporting our findings from ELISAs, we
observed a significant increase in IL-27p28 expression following
poly(I:C) and LPS stimulation in IRAK12/2 BMDM compared
with WT BMDM [p , 0.05, poly(I:C); p , 0.001, LPS; Fig. 1E].
EBI3 mRNA levels were increased basally in IRAK12/2 BMDM
and increased further, albeit not significantly, following LPS and
poly(I:C) stimulation compared with WT macrophages (Fig. 1F).
This finding indicates that IRAK1 negatively regulates the EBI3
subunit also in a stimulus-independent manner. In parallel, we
assessed whether blocking the kinase activity of TBK1/IKKε
influenced IL-27 subunit expression in both WT and IRAK1-
deficient macrophages. MRT67307 reduced IL-27p28 subunit
FIGURE 2. IRAK1 regulates IRF1 and IRF9, key transcription factors controlling IL-27p28 expression. (A and E) WT and IRAK12/2 BMDM were
stimulated with poly(I:C) (25 mg/ml) or LPS (1 mg/ml) for the indicated times, and whole cell lysates were generated. Cell lysates were resolved by
SDS-PAGE (10%) and subjected to immunoblotting for IRF1, IRF9, and IRAK1, with b-actin as a loading control. Similar results were obtained in two
independent experiments. (B and F) WT and IRAK12/2 BMDM were pretreated with DMSO or MRT67307 (2 mM) for 1.5 h prior to stimulation with
25 mg/ml poly(I:C) or 1 mg/ml LPS for 3 h. Total RNA was isolated and subjected to reverse transcription. IRF1 and IRF9 mRNA were measured by
quantitative real time RT-PCR, normalized against GAPDH mRNA, and shown as the mean (6SEM) of three independent experiments performed in
triplicate. One-way ANOVA with a post hoc Tukey test was conducted for multiple experimental group comparison. (C and D) Where indicated, WT and
IRAK12/2 BMDM were pretreated with DMSO or MRT67307 (2 mM) for 1.5 h prior to stimulation with 25 mg/ml poly(I:C) or 1 mg/ml LPS for the
indicated times, and nuclear lysates were generated. Lysates were subjected to immunoblotting with the indicated Abs. Similar results were obtained in two
independent experiments.
Table I. Primer sequences for real-time PCR
Gene Forward Reverse
mIL-27 p28 59-CTC TGC TTC CTC GCT ACC AC-39 59-GGG GCA GCT TCT TTT CTT CT-39
mEBI3 59-TGA AAC AGC TCT CGT GGC TCT A-39 59-GCC ACG GGA TAC CGA GAA-39
mGAPDH 59-CCA TGC CAT CAC TGC CAC CCA GAA-39 59-GTC CAC CAC CCT GTT GCT GTA GCC-39
mIRF1 59-TCG TCA GCA GCA GTC TCT CT-39 59-TTC GGC TAT CTT CCC TTC CT-39
mIRF9 59-GTC TGG AAG ACT CGC CTA CG-39 59-GTG ATT TCT GGT TCC GTG GT-39
mSTAT1 59-AAG CGA ACT GGA TAC ATC A-39 59-CCG GGA CAT CTC ATC AAA C-39
hIL-27p28 59-GCG GAA TCT CAC CTG CCA-39 59-GGA AAC ATC AGG GAG CTG CTC-39
hEBI3 59-TAA CAG AGC ACA TCA TCA AG-39 59-TTG AGT GAG AAG ATC TCT GG-39
hGAPDH 59-ACA GTT GCC ATG TAG ACC-39 59-TTG AGC ACA GGG TAC TTT A-39
hSTAT1 59-ACC CAA TCC AGA TGT CTA TG-39 59-GAG CCT GAT TAA ATC TCT GG-39
hIRF1 59-ATA CCT TCT CTG ATG GAC TC-39 59-GAA GTT GTA CAG ATC ACT GG-39
hIRF9 59-CTC AGA AAG TAC CAT CAA AGC-39 59-TCA TTA TTG AGG GAG TCC TG-39
hSTAT2 59-ATA TAA GAT CCA GGG CCA AAG G-39 59-CAG TAG CTC GAT TAG GGT AG-39
hIFN-b 59-ATT CTA ACT GCA ACC TTT CG-39 59-GTT GTA GCT CAT GGA AAG AG-39
h, human; m, murine.
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expression in WT macrophages stimulated by both LPS (351-fold
versus 119-fold; NS) and poly(I:C) (71-fold versus 10-fold; NS)
ligands. Pretreatment of IRAK12/2 BMDM with MRT67307 re-
duced the increase in IL27p28, with a more pronounced reduction
observed in LPS-stimulated IRAK12/2 BMDM (p , 0.001;
Fig. 1E) when compared with poly(I:C) (257-fold versus 117-fold;
NS, Fig. 1E), paralleling our findings from ELISAs (Fig. 1C).
Pretreating WT or IRAK12/2 BMDM with MRT67307 failed to
influence EBI3 mRNA expression at the basal level or following
ligand stimulation.
IRAK1 regulates IRF1 and IRF9, key regulators of
IL-27p28 expression
Previous studies have shown that IRF1, IRF3, and IRF9 play pivotal
roles in IL-27p28 expression downstream of both TLR3 and TLR4
(4). Therefore, we next addressed the role of IRAK1 in the reg-
ulation of these transcription factors.
We observed higher protein levels of IRF1 in IRAK12/2 BMDM
compared with WT BMDM following both LPS and poly(I:C)
ligand stimulation conditions, and this increase in IRF1 was noted
at earlier time points in IRAK1-deficient macrophages (Fig. 2A).
To determine if this increase in IRF1 protein is reflected at the
mRNA level, we examined for differences in mRNA expression
levels of IRF1 by qRT-PCR in WT versus IRAK12/2 BMDM
following poly(I:C) and LPS stimulation (Fig. 2B). A modest
increase in the basal levels of IRF1 mRNA was observed in
IRAK12/2 BMDM compared with WT macrophages. However,
following ligand stimulation, the observed increase in IRF1
mRNA levels in IRAK1-deficient macrophages was quite
marked [120-fold in IRAK12/2 versus 15-fold in WT BMDM
following poly(I:C) stimulation and 70-fold in IRAK12/2 versus
15-fold following LPS stimulation; Fig. 2B]. Pretreatment of WT
macrophages with MRT67307 reduced TLR4-induced (15-fold
versus 3-fold in MRT67307) and TLR3-induced (15-fold versus 4-
fold in MRT67307) IRF1 mRNA levels (Fig. 2B). Using
MRT67307 in IRAK12/2 BMDM led to a reduction in IRF1
mRNA levels in poly(I:C)-stimulated, IRAK1-deficient macro-
phages (120-fold versus 62-fold in MRT67307); a more pro-
nounced reduction was seen in LPS-stimulated cells (70-fold
versus 16-fold in MRT67307-pretreated IRAK12/2 BMDM) (Fig.
2B). Examining IRF1 regulation further, we observed a marked
increase in the nuclear levels of IRF1 in IRAK12/2 macrophages
compared with WT macrophages at 3 h post–ligand stimulation
(Fig. 2C). In response to LPS, we observed high nuclear levels of
IRF1 as early as 1 h post–ligand stimulation in IRAK12/2 mac-
rophages (Fig. 2D). Pretreatment of WT BMDM with MRT67307
led to reduced nuclear levels of IRF1 following LPS and poly(I:C)
ligand stimulation conditions (Fig. 2C). Using MRT67307 in the
IRAK12/2 BMDM, we observed only a modest reduction in the
nuclear levels of IRF1 following poly(I:C) and LPS stimulation.
Reduced IRF1 nuclear levels may be explained in part by our
findings that MRT67037 leads to a decrease in TLR ligand–in-
duced IRF1 mRNA expression in both WT and IRAK1-deficient
macrophages (Fig. 2B).
We have previously shown that hyperactivation of IRF3 occurs in
IRAK12/2 compared with WT BMDM following TLR3 activation
FIGURE 3. IRAK1 regulates STAT1 activation and expression levels following TLR3 and TLR4 stimulation. (A and B) WTand IRAK12/2 BMDM were
stimulated with poly(I:C) (25 mg/ml) or LPS (1 mg/ml) for the indicated times, and whole cell lysates were generated. Cell lysates were resolved by
SDS-PAGE (10%) and subjected to immunoblotting for p-STAT1 (Y701), p-STAT1 (S727), and total STAT1, with b-actin as a loading control. Similar
results were obtained in three independent experiments. (C) WT and IRAK12/2 BMDM were stimulated with 25 mg/ml poly(I:C) or 1 mg/ml LPS for 1 and
3 h, and nuclear lysates were generated. Lysates were subjected to immunoblotting with the indicated Abs. Similar results were obtained in three inde-
pendent experiments. (D and E) Relative ratio of phospho-STAT1/PCNA (nuclear loading control) in WT and IRAK12/2 BMDM at 1 and 3 h following
poly(I:C) and LPS stimulation, as determined by densitometric analysis of three independent experiments.
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(35). In this study, we observed no increase in IRF3 activa-
tion in IRAK12/2 BMDM following TLR4 ligand stimulation
(Supplemental Fig. 1).
IRF9 is thought to act primarily downstream of IFNAR as part of
the ISGF3 complex, influencing the expression of a vast number of
IFN-stimulated genes, including IL-27p28 (4, 36). To date, limited
data have been published on factors regulating IRF9 or indeed its
biological role in TLR signaling (36). We observed increased IRF9
protein levels in IRAK12/2 compared with WT BMDM in unsti-
mulated cells and following poly(I:C) and LPS stimulation
(Fig. 2E). Profiling nuclear IRF9 revealed that IRAK1-deficient
macrophages consistently showed increased nuclear levels of
IRF9 following LPS and poly(I:C) stimulation compared with WT
macrophages (Fig. 2C, 2D). MRT67307 had a minimal effect on the
high nuclear levels of IRF9 observed in TLR ligand–stimulated
IRAK12/2 macrophages (Fig. 2C). Next, we examined whether
IRAK1 regulates IRF9 at the transcriptional level. Increased IRF9
mRNA was observed basally and following poly(I:C) and LPS
stimulation of IRAK12/2 macrophages compared with WT mac-
rophages (Fig. 2E). Pretreating IRAK12/2 or WT BMDM with
MRT67307 failed to influence either basal or ligand-stimulated
levels of IRF9 mRNA (Fig. 2F). Taken together, these data reveal
that members of the noncanonical IkB kinases TBK1 or IKKε are
involved in the transcriptional regulation of IRF1 but not IRF9.
The identification of IRAK1 as a novel regulator of STAT1
STAT1 is critically involved in IL-27p28 gene transcription
downstream of IFNAR. Phosphorylation of STAT1 at S727 occurs
independently of autocrine IFN signaling for TLR4; in contrast, a
dependency on the IFNAR pathway has been speculated but not
proven conclusively for TLR3 (37). STAT1 phosphorylation at
Y701 downstream of TLR3 and TLR4 is dependent on autocrine
type I IFN signaling (37). Increased activation of STAT1 was seen
in IRAK12/2 compared with WT macrophages following both
LPS and poly(I:C) ligand stimulation conditions (Fig. 3A, 3B).
Examining nuclear levels of STAT1, we observed increased
levels of p-STAT1 in IRAK1-deficient macrophages compared
with WT macrophages and at the earlier time point of 1 h after
ligand stimulation (Fig. 3C–E). Further profiling revealed a
marked increase in the basal levels of total STAT1 in IRAK1-
deficient macrophages (Fig. 3A, 3B). To our knowledge, this
represents the first study to show that IRAK1 regulates STAT1
activation downstream of TLRs and furthermore identifies
IRAK1 as a novel modulator of STAT1 expression. Examining
this finding further, we performed quantitative real-time PCR to
assess the relative expression of STAT1 in IRAK12/2 compared
with WT macrophages. In unstimulated cells, we observed
higher mRNA levels for STAT1 in IRAK12/2 versus WT
BMDM, with the same finding observed following stimulation
with poly(I:C) and LPS (Fig. 4A). Pretreatment of WT and
IRAK12/2 BMDM with MRT67307 reduced STAT1 expression
levels following stimulation with poly(I:C) or LPS (Fig. 4A).
Next, we stimulated WT and IRAK12/2 macrophages with poly
(I:C) and LPS, in the presence or absence of MRT67307, and
examined nuclear levels of p-STAT1 (Y701), which is dependent
on IFNAR signaling (Fig. 4B). A marked increase in the nuclear
levels of p-STAT1 was clearly observed in IRAK12/2 compared
with WT macrophages. The heightened nuclear levels of
p-STAT1 seen in IRAK12/2macrophages were greatly reduced
by MRT67307 following TLR4 ligand stimulation. In contrast,
MRT67307 barely affected p-STAT1 nuclear levels following
poly(I:C) stimulation of IRAK12/2 macrophages (Fig. 4B),
possibly due to sustained IFN-b production driving STAT1 activation
(Fig. 1D).
Because STAT1 expression together with activity are increased
in IRAK12/2 macrophages, we decided to address whether
blocking STAT1 could significantly impact the elevated IL-27
FIGURE 4. (A) WT and IRAK12/2 BMDM were pretreated with DMSO
or MRT67307 (2 mM) for 1.5 h prior to stimulation with 25 mg/ml poly(I:C) or
1 mg/ml LPS for 3 h. Total RNA was isolated and subjected to reverse tran-
scription. STAT1 mRNA was measured by quantitative real time RT-PCR,
normalized against GAPDH mRNA, and shown as the mean (6SEM) of three
independent experiments performed in triplicate. One-way ANOVAwith a post
hoc Tukey test was conducted for multiple experimental group comparison.
(B) WT and IRAK12/2 BMDM were pretreated with DMSO or MRT67307
(2 mM) for 1.5 h prior to stimulation with 25 mg/ml poly(I:C) or 1 mg/ml LPS
for 3 h, and nuclear lysates were generated. Lysates were subjected to im-
munoblotting with the indicated Abs. Similar results were obtained in three
independent experiments. (C) STAT1 is required for IL-27 production down-
stream of both TLR3 and TLR4. WT or IRAK12/2 BMDM were seeded and
stimulated for 9 h with 25 mg/ml poly(I:C) or for 6 h with 1 mg/ml LPS. Cells
had been pretreated with 50 mM fludarabine (STAT1 inhibitor) or the same
volume of DMSO as a vehicle control for 24 h. Supernatants were collected,
and IL-27 levels were measured by ELISA. The p values were calculated using
the unpaired Student t test. *p , 0.05, **p , 0.01. NL, no ligand.
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levels observed in IRAK12/2 BMDM. Fludarabine, a nucleoside
analog, inhibits STAT1, and work has shown that it depletes STAT1
at the mRNA and protein level while not affecting other STAT
members (38). Pretreating IRAK12/2 BMDM with fludarabine
significantly reduced IL-27 production following LPS (p , 0.01)
and poly(I:C) (p , 0.05) ligand stimulation conditions (Fig. 4C).
Altogether, we have uncovered a novel function of IRAK1 in reg-
ulating STAT1 expression and activation.
IRAK1 regulates the key transcription factors involved in
TLR-induced IL-27 production in a human microglial cell line
We successfully generated stable knockdown for IRAK1 in hu-
man microglial cells (CHME3) and used a nontargeting control
shRNA for control cells. We found significantly increased IL-27
levels in IRAK1 knockdown cells compared with control cells
following LPS and poly(I:C) stimulation [p , 0.05, poly(I:C);
p , 0.05, LPS; Fig. 5A]. Interestingly, we also observed increased
basal levels of IL-27 in IRAK1 knockdown cells (p , 0.01).
Western blot analysis confirmed knockdown of IRAK1 in the
microglial cells (∼80–90%) used for ELISA (Fig. 5B). Because
STAT1 is key to the mechanistic understanding of the observed
increase in IL-27, we next profiled IRAK1 knockdown cells
compared with control cells by Western blot analysis. LPS- and
poly(I:C)-stimulated IRAK1 knockdown cells showed increased
activation of STAT1 as well as increased expression of IRF1,
IRF9, and STAT1 compared with control cells (Fig. 5C).
IRAK1 regulates IL-27 production downstream of IFNAR
Assessing levels of IL-27 by ELISA in IFN-b–stimulated WT and
IRAK1-deficient macrophages revealed a significant increase in
IL-27 production in the IRAK12/2 compared with WT macro-
phages (p , 0.01, 6 h; Fig. 6A). We next examined IL-27 at the
transcriptional level, measuring p28 and EBI3 subunit expression
by qRT-PCR in IFN-b–stimulated control and IRAK1 knockdown
human microglial cells (CHME3). We observed an increase in
IL-27p28 expression (10-fold versus 3-fold) and EBI3 (6-fold
versus 2-fold) following IFN-b stimulation in IRAK1 knockdown
compared with control cells (Fig. 6B, 6C). Examining the key
transcription factors regulating IL-27p28 expression downstream
of IFNAR, we found increased expression of IRF1, IRF9, STAT1,
and STAT2 at the basal level as assessed by qRT-PCR (Fig. 6D–G).
For IRF1 and IRF9, a marked increase in mRNA expression levels
was observed in response to IFN-b in IRAK1 knockdown cells
(Fig. 6F, 6G). Type I IFN signaling leads to the formation of
ISGF3 and STAT1 homodimers; the latter positively regulates
IRF1 gene expression by its binding to the IFN-g activation site.
Our findings prompted us to examine nuclear levels of activated
STAT1 in IFN-b–stimulated, IRAK1-deficient macrophages
compared with WT macrophages (Fig. 7). We detected increased
nuclear levels of p-STAT1, IRF1, and IRF9 in IRAK1-deficient
macrophages compared with WT macrophages (Fig. 7). A marked
increase in the nuclear levels of IRF1 was observed as early as 1 h
after IFN-b stimulation in IRAK1-deficient macrophages
(Fig. 7A, 7E). Next, through Western blot analysis of whole cell
lysates generated from control and IRAK1 knockdown human
microglial cells, we showed increased basal levels of IRF1, IRF9,
STAT1, and STAT2 as well as increased IRF1/9 levels following
IFN-b stimulation (Fig. 8A). Increased activation of STAT1 was
observed in IRAK1 knockdown cells compared with control cells
following IFN-b stimulation, whereas we observed less marked
differences in the activation profile for STAT2 (Fig. 8A). Examining
IFN-b mRNA expression by qRT-PCR showed a significant in-
crease in the basal expression of IFN-b in IRAK1 knockdown cells
compared with control cells (Fig. 8B). Blocking the kinase activ-
ity of TBK1/IKKε with MRT67307 in IRAK1 knockdown cells
FIGURE 5. IRAK1 regulates the TLR3/4–STAT1–IL-27 signaling in human microglial cells. (A) Stable IRAK1 knockdown (IRAK1sh; short-hairpin
RNA) and control (Ctrolsh) human microglial cells (CHME3) were stimulated with 25 mg/ml poly(I:C) or 1 mg/ml LPS. Supernatants were collected after
12 h, and IL-27 levels were measured through ELISA. Data are the mean (6SEM) of four independent experiments performed in triplicate. The p values
were calculated using the unpaired Student t test. *p, 0.05, **p, 0.01. (B) Lysates were generated from IRAKsh and Ctrolsh wells following supernatant
collection for ELISA experiments shown in Fig. 4A, which were subsequently subjected to immunoblotting with IRAK1 and b-actin Abs to validate
knockdown of IRAK1. (C) IRAKsh and controlsh cells were stimulated with 25 mg/ml poly(I:C) or 1 mg/ml LPS for the indicated times, and whole cell
lysates were generated. Cell lysates were resolved by SDS-PAGE (10%) and subjected to immunoblotting with the indicated Abs. Similar results were
obtained in three independent experiments. NL, no ligand.
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reduced STAT1/2 protein levels as assessed by Western blot anal-
ysis (Fig. 8C–E). These results prompted us to profile STAT1 ex-
pression and activation by immunoblot analysis in TBK1-deficient
macrophages. We observed reduced activation and expression levels
of STAT1 in LPS and poly(I:C) ligand–stimulated TBK12/2 mac-
rophages compared with their control counterpart cells (Fig. 9A,
9B). We also observed a slight reduction in total STAT2 levels in
TBK1-deficient macrophages compared with control cells (Fig. 9A,
9C). Not surprisingly, TBK1-deficient macrophages showed im-
paired IL-27 cytokine production compared with control BMDM
following LPS (p , 0.01, 6 h) and poly(I:C) (p , 0.05, 6 h) ligand
stimulation conditions (Fig. 9D).
Discussion
We reported previously that IRAK1 limits TLR3-induced IFN-b pro-
duction (35), whereas LPS-stimulated, IRAK1-deficient macrophages
showed comparable IFN-b levels to control cells (35). In con-
trast to these findings for IFN-b, IRAK1 limits TLR3- and
TLR4-induced IL-27 production. Knowledge that IRF3 is an
important transcriptional regulator of IL-27p28 expression
prompted us to examine whether TBK1, the IRF3-activating
kinase, played a significant role in TLR3/4-driven IL-27 pro-
duction. Pretreating WT macrophages with a dual TBK1/IKKε
kinase inhibitor significantly reduced both LPS- and poly(I:C)-
induced IL-27p28 expression and IL-27 cytokine levels. In
contrast to IL-27p28 subunit expression, blocking TBK1/IKKε
kinase activity failed to influence ligand-induced EBI3 subunit
expression under the same stimulation conditions. IRAK1-
deficient macrophages showed increased expression of EBI3
mRNA following LPS and poly(I:C) stimulation, most notably
following LPS stimulation. This points to the hyperactivation of
an NF-kB–independent mechanism regulating EBI3 expression
FIGURE 6. IRAK1 regulates IL-27 production
downstream of IFNAR. (A) WT and IRAK2/2
BMDM were seeded at a concentration of 1 3 106
cells/ml and treated the following day with 10 ng/ml
murine IFN-b or no ligand (NL) for 8 h. Cell
supernatants were then collected, and IL-27 con-
centration was measured by ELISA. The mean
6 SD of six independent experiments, performed in
triplicate, is shown. The p values were calculated
using the unpaired Student t test. **p , 0.01. (B–G)
Stable IRAK1 knockdown (IRAK1sh; short-hairpin
RNA) and control (Ctrolsh) human microglial cells
(CHME3) were seeded at 5 3 105 cells/ml and
treated the next day with NL and 10 ng/ml of hu-
man IFN-b for 2 h. Total RNA was isolated and
subjected to qRT-PCR for the indicated targets,
normalized against GAPDH mRNA, and shown as
the mean (6SEM) of four independent experiments
performed in triplicate.
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because IRAK1 deficiency reduces NF-kB activation following
LPS stimulation.
Focusing on how IL-27p28 expression is regulated, we investi-
gated whether deregulated expression/activity of IRF1/3/9 accounted
for higher TLR stimulus-driven IL-27p28 expression observed in
IRAK1-deficient macrophages. We observed earlier induction and
higher expression levels of IRF1, including pronounced nuclear
levels, following LPS and poly(I:C) stimulation in IRAK1-deficient
macrophages compared with control cells. TLR4-induced expression
and activation of IRF1 is dependent on MyD88 (31), whereas TLR3-
induced activation of IRF1 is presumed to rely on autocrine IFN-b
signaling (2). Previous work has shown a positive role for IRF1 in
the early phase of LPS-induced IL-27p28 gene expression (2-h time
point) and a later phase downstream of IFNAR following LPS and
poly(I:C) ligand stimulation (2). STAT1 is known to regulate IRF1
expression (39), which most likely contributes to the increase
in IRF1 levels observed following LPS, poly(I:C), and IFN-b
stimulation in IRAK1-deficient macrophages, which show hyper-
activation of STAT1.
TLR3/4-stimulation led to pronounced nuclear levels of IRF9 in
IRAK1-deficient macrophages compared with control cells ac-
companied by increased expression at the mRNA and protein level
in unstimulated cells. Work using IRF9-deficient dendritic cells has
previously defined a crucial role for IRF9 in poly(I:C)-driven early
and late phase IL-27p28 expression, whereas a dependency on late
phase p28 expression was reported for IRF9 downstream of TLR4
(4). Most certainly, the observed increase in IRF9 contributes to
the heightened levels of TLR3/4 stimulus-driven IL-27 in IRAK1-
deficient macrophages. IRF9 expression is regulated by STAT1
and IRF1 (39), which may explain the increase observed in
IRAK1-deficient cells.
Interestingly, this work has unfolded a novel regulatory role for
IRAK1 in STAT1 activation. Previous studies determined a re-
quirement for the scaffold function of IRAK1 in IL-1–induced
S727 phosphorylation of STAT1 (40). In contrast to IL-1R sig-
naling, we report hyperactivation of STAT1 (S727) following
LPS and poly(I:C) stimulation in both murine and human
IRAK1-deficient immune cells. In TLR4 signaling, phosphory-
lation of STAT1 at S727 is dependent on MyD88 and TRIF
signaling but independent of IRF3, IRF7, and IFNAR (37). Re-
cent work highlighted a role for STAT1 (S727) in the regulation
of TNF-a production downstream of several TLRs, including
TLR4, but to date, knowledge of TLR-specific, STAT1-regulated
genes is limited (37).
TLR-induced activation of STAT1 at Y701 is considered IFNAR
signaling dependent (37). In IRAK1-deficient macrophages, TLR-
induced STAT1 hyperphosphorylation (Y701) prompted us to
examine whether IRAK1 could be controlling IL-27 expression
beyond the TLR-specific phase. Stimulating IRAK1-deficient
macrophages with IFN-b led to heightened IL-27 cytokine lev-
els accompanied by increased nuclear levels of p-STAT1 and IRF1
compared with control macrophages. To our knowledge, this work
FIGURE 7. (A) WT and IRAK12/2 BMDM were stimulated with mIFN-b (10 ng/ml) for the indicated time points, and nuclear lysates were
generated. Lysates were subjected to immunoblotting with the indicated Abs. Similar results were obtained in three independent experiments.
(B) Relative ratio of p-STAT1(Y701)/PCNA (nuclear loading control), (C) p-STAT1(S727)/PCNA, (D) total STAT1/PCNA, (E) IRF1/PCNA, and
(F) IRF9/PCNA in WT and IRAK12/2 BMDM following mIFN-b stimulation, as determined by densitometric analysis of three independent
experiments.
2078 IRAK1 LIMITS TLR3/4- AND IFNAR-DRIVEN IL-27 PRODUCTION
 at M
aynooth U
niversity (Natl Univ of Ireland) on February 3, 2020
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
provides the first evidence that IRAK1 acts downstream of
IFNAR, regulating the activity of STAT1 and, consequently, the
expression of STAT1 target genes. IRAK1 may be involved in the
regulation of phosphatases or kinases controlling STAT1 activa-
tion downstream of both TLR and IFNAR signaling pathways.
We found that IRAK1 controls the basal levels of STAT family
members STAT1 and STAT2. We detected higher mRNA and
protein levels of STAT1 and STAT2 in IRAK1 knockdown com-
pared with control cells. Previous work has shown that STAT1
protein levels are reduced in dendritic cells isolated from cata-
lytically inactive IRAK1 (D359) mice (41). Considering these data,
we may suggest that the scaffold and kinase function of IRAK1
are both required to maintain normal basal levels of STAT1. Low-
level IFN-b signaling is required to maintain adequate levels of
STAT1 and its target genes, as evidenced by diminished STAT1
protein levels observed in IFNAR, IRF3, TRIF, and TRAM-
deficient macrophages (42–44). In earlier work, we observed
hyperactivation of TBK1 in unstimulated, IRAK1-deficient
macrophages (35). We speculate that hyperactivated TBK1
may contribute to the observed increase in STAT1/2 protein
levels by supporting an increase in autocrine IFN-b signaling,
driving IRF1 expression, a known transcriptional regulator of
STAT1 and STAT2 (39). Supporting this possibility, we ob-
served an increase in IFN-b and IRF1 mRNA levels in unsti-
mulated IRAK1 knockdown cells compared with control cells.
Indeed, treating IRAK1-deficient microglial cells with a TBK1/
IKKε kinase inhibitor almost reduced STAT1/2 protein to levels
observed in control cells. Furthermore, TBK1-deficient mac-
rophages showed reduced levels of STAT1 and STAT2, sup-
porting our idea that TBK1 is actively involved in the
maintenance of autocrine IFN-b signaling in cells. IRAK1 may
additionally participate in the regulation of STAT1 expression at
the posttranslational level, perhaps by controlling the activity of
E3 ubiquitin ligases. Several have already been functionally
FIGURE 8. IRAK1 is involved in the regulation of the STAT-IRF signaling axis downstream of IFNAR. (A) Stable IRAK1 knockdown (IRAK1sh; short-
hairpin RNA) and control (Ctrolsh) human microglial cells (CHME3) were seeded at a density of 5 3 105 cells/ml. The next day, the cells were stimulated
with IFN-b (10 ng/ml) and harvested at the indicated times (0–4 h). The resulting lysates were resolved by SDS-PAGE (10%) and subjected to immu-
noblotting for p-STAT1 (Y701), p-STAT1 (S727), total STAT1, p-STAT2 (Y690), total STAT2, IRF1, IRF9, and IRAK1, with b-actin as a loading control.
Similar results were obtained in three independent experiments. (B) CHME3 Ctrolsh and IRAK1sh cells were seeded at 5 3 105 cells/ml, and the next day,
total RNA was isolated and subjected to qRT-PCR for IFN-b, normalized against GAPDH mRNA, and shown as the mean (6SEM) of five independent
experiments performed in triplicate. The p values were calculated using the unpaired Student t test. **p , 0.01. (C) IRAKsh and controlsh cells were
treated with MRT67307 (2 mM) for 48 h, and whole cell lysates were generated. Cell lysates were resolved by SDS-PAGE and subjected to immunoblotting
with the indicated Abs. Similar results were obtained in three independent experiments. (D and E) Relative ratio of total STAT1/b-actin and total STAT2/
b-actin in DMSO- and MRT67307-treated IRAKsh and controlsh cells, as determined by densitometric analysis of three independent experiments.
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linked to STAT1 expression, including SLIM, Smurf1, and c-Cbl
(45–47).
In conclusion, we have identified IRAK1 as a novel regulator of
STAT1 expression and activation downstream of TLR and IFNAR
signaling pathways. We speculate that increased STAT1/2 ex-
pression found in IRAK1-deficient cells is driven by highly con-
stitutive IFN-b signaling mediated by hyperactive TBK1. Future
work will address exactly how IRAK1 regulates the activation of
STAT1 in these pathways and whether this regulation is kinase
dependent. Overall, this study uncovers mechanistic details about
the complex regulation of IL-27, a key immunomodulatory cy-
tokine of relevance to cancer and autoimmune diseases.
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